Myth: Filing Early Means Strong Protection (Not Always True in Biotech) 22 May 2026 “File early” is one of the most common principles in patent strategy, especially in biotech. The logic is easy to understand. In a competitive research environment, securing an early priority date matters. No company wants to lose rights because it waited too long to file. But in biotech, early filing does not automatically lead to strong protection. In fact, filing too early can sometimes produce the opposite result. An application may secure a priority date, yet still fail to deliver meaningful patent coverage if the underlying disclosure is not strong enough to support what is being claimed. This is where an important distinction is often overlooked: filing early and filing well are not always the same thing. Biotech inventions are particularly vulnerable to this problem because the science is often complex, the underlying biology can be unpredictable, and commercially important claim scope often depends on demonstrating effects that are not easy to generalize. A filing may look ambitious on paper, with broad claims and wide-ranging embodiments, but still be exposed if the supporting data is too thin at the filing date. That tension appears across many areas of biotech. It can arise in therapeutic inventions, platform technologies, biologics, diagnostics, biomarkers, formulations, dosing strategies, combination treatments, and patient stratification approaches. In each of these areas, there is often pressure to file as soon as a promising signal appears. That pressure is understandable. Early filing can preserve options and reduce the risk of losing priority. But when a filing is built around what the invention might eventually become, rather than what the application can already support, the resulting protection may be much weaker than expected. This is one reason breadth in biotech is often easier to draft than to defend. Second medical use claims offer a useful example, but the lesson is much broader than that category alone. Where a known compound is being claimed for a new therapeutic use, the central issue is often whether the application makes the claimed therapeutic effect credible at the filing date. More broadly, whenever a patent application seeks protection that extends beyond what the data can reasonably support, vulnerability is introduced. This is why early filing can backfire. An application filed too soon may contain claims that are broader than the available evidence can sustain. It may rely too heavily on hypothesis, extrapolation, or future-looking assumptions. During prosecution, that gap often becomes difficult to defend. Claims may need to be narrowed significantly, and the granted patent may end up covering much less than the original commercial objective. In some cases, the application may not survive prosecution at all. The more effective approach in biotech is not to delay until perfect data exists. Waiting for complete validation can also be risky, and in fast-moving fields it may mean waiting too long. The real challenge is to identify the point at which the filing is early enough to secure position, but mature enough to support meaningful protection. That usually requires discipline in three areas. First, the filing should contain enough technical support to make the invention credible at the filing date. That does not necessarily mean clinical data, but it does mean more than a speculative concept. Depending on the invention, relevant in vitro data, in vivo results, mechanistic support, or other technically persuasive evidence may be needed. Second, the scope of the disclosure and claims should be aligned with what the data can reasonably support. Ambition in drafting is valuable, but unsupported breadth often creates fragility rather than strength. Third, patent strategy should be viewed as staged rather than singular. Additional data developed over time can support later filings directed to expanded indications, refined subgroups, optimized regimens, or other commercially important developments. The broader lesson is that in biotech, patent strength is not determined by timing alone. Priority date matters, but support matters just as much. An early filing can only create durable value if the application contains enough substance to withstand scrutiny later.